Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

218.91 -2.84 (-1.28%)
Streaming Delayed Price Updated: 11:16 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target.... 
Via Benzinga
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China
From BeiGene
Via Business Wire
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
From BeiGene
Via Business Wire
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
From BeiGene
Via Business Wire
BeiGene Unveils Results From Late-Stage Tislelizumab In Nasopharyngeal Cancer
BeiGene Ltd (NASDAQ: BGNE) revealed the detailed data from the Phase 3 RATIONALE 309 trial of tislelizumab for nasopharyngeal cancer. The trial evaluated... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. It is the third listing for the company,... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman Disease
The China National Medical Products Administration has approved BeiGene Ltd (NASDAQ: BGNE) / EUSA Pharma (UK) Ltd's Sylvant (siltuximab) for adult... 
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib
From BeiGene
Via Business Wire
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
From BeiGene
Via Business Wire
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
From BeiGene, Ltd.
Via Business Wire
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... 
Via Talk Markets
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
BeiGene's Brukinsa Approved In Europe For Rare Type Of Blood Cancer
The European Commission has approved BeiGene Ltd's (NASDAQ: BGNE) BRUKINSA (zanubrutinib) for Waldenström's macroglobulinemia (WM). WM is a type of... 
Via Benzinga
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
From BeiGene, Ltd.
Via Business Wire
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
From BeiGene, Ltd.
Via Business Wire
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
From BeiGene
Via Business Wire
Week In Review: BeiGene Cleared To Stage $3 Billion IPO On Shanghai STAR Exchange
Beijing's BeiGene was approved to stage a $3 billion IPO on Shanghai’s STAR Exchange, the company's third listing. Previously, the company completed an $182 million IPO on the NASDAQ in 2016 and a $900... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
From BeiGene
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.